Extension of esketamine study shows long‐term safety in treatment‐resistant depression

A two‐year extension of a trial of esketamine nasal spray in patients with treatment‐resistant depression has found no new safety concerns associated with long‐term use of the drug. The overall relapse rate across both the original trial and the extension was 6.9%.

Publication Details

Journal
The Brown University Psychopharmacology Update
Published
2026-04-30
DOI
https://doi.org/10.1002/pu.31451
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Extension of esketamine study shows long‐term safety in treatment‐resistant depression

The Brown University Psychopharmacology Update
Treatment of Major Depression
article

Extension of esketamine study shows long‐term safety in treatment‐resistant depression

article en

Abstract

A two‐year extension of a trial of esketamine nasal spray in patients with treatment‐resistant depression has found no new safety concerns associated with long‐term use of the drug. The overall relapse rate across both the original trial and the extension was 6.9%.

The Brown University Psychopharmacology UpdateVol. 37(6)
Good health and well-being
Openalex Percentile: Top 9%
Treatment of Major Depression
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Extension of esketamine study shows long‐term safety in treatment‐resistant depression · The Brown University Psychopharmacology Update (2026) | TGRS Research Map | TGRS